Learn about INVOKANA®, an SGLT2 inhibitor that helps lower blood sugar and risk of cardiovascular disease in adults. See full Prescribing & Safety Info. INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an INVOKANA mg once daily who have an eGFR of 60 mL/min/ m2. INVOKANA® is now the only oral diabetes treatment approved to in the INVOKANA® U.S. full Prescribing Information (PI).3 The PI also.

Author: Goltile Shakarisar
Country: Georgia
Language: English (Spanish)
Genre: Relationship
Published (Last): 20 January 2011
Pages: 125
PDF File Size: 3.1 Mb
ePub File Size: 9.75 Mb
ISBN: 846-6-95163-531-7
Downloads: 63015
Price: Free* [*Free Regsitration Required]
Uploader: Faegal

Invokana, known generically as canagliflozin, is in a class of drugs called the sodium-glucose transporter-2 SGLT2 inhibitors. Major illness, reduced food and fluids, and reduced insulin doses can also cause ketoacidosis. A higher rate of serious infections has also been observed in RA patients treated with rituximab who received subsequent treatment with a TNF blocker. Published trial for Canagliflozin Hermansen, K et al. Patients invvokana a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications.

Please see full Prescribing Information. The submission did not anticipate any cost consequences with the PBS listing of canagliflozin, but did not account for any costs related to the management of adverse events.

Other options include glucagon like peptide 1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and thiazolidinediones.

The PBAC noted the variation in usage estimates presented in this submission compared to the other sodium glucose transporter 2 inhibitor being considered for subsidy at this meeting, and requested the Department work with both invvokana to develop a single set of estimates. However, in Maythe FDA issued an important warning that the SGLT2 inhibitors like canagliflozin can infrequently cause ketoacidosis, usually in less than 1 out of every patients.

Available for Android and iOS devices. Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Recommended Recommended listing Add the following new items: You ivnokana need a dose reduction if you have kidney impairment, or for severe kidney disease, you may not be able to use Invokana at all.


The PBAC did not consider this claim to be reasonable, agreeing that infections could be more common in non-trial populations, and considered that the cost of managing infections related to treatment should be accounted for.

Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, laryngeal edema and pulmonary edema. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis.

Invokana Insights: 10 Drug-Specific Facts You Should Know

However, rash that was considered drug invokaa occurred at similar rates. The PBAC considered also that prescribing of canagliflozin outside the proposed PBS restriction may be driven by its effects on weight loss, as well as the observed high utilisation of sitagliptin the main comparator outside its PBS listing. The PBAC noted the small patient numbers in the Phase III studies with long term exposure to canagliflozin and considered that the long term safety is unclear. Interference with Determination of Complete Response — Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis SPE and invikana IFE assays used for the clinical monitoring of endogenous M-protein.

Monitor patients frequently for signs and symptoms of neurological impairment. The FDA stated that patients who experience signs or symptoms of ketoacidosis such as trouble breathing, nausea, vomiting, abdominal [stomach] pain, confusion, unusual fatigue or sleepiness should contact their doctor immediately to determine if they have ketoacidosis, as your drug treatment may need to be stopped.

Monitor patients with neutropenia for signs of infection.

New Drug Approved for Type 2 Diabetes. Monitor patients for hypertension, hypokalemia, and fluid retention at least once a month. Cases of leukopenia, neutropenia, pj, and pancytopenia some fatal have been reported.

The most common Invokana side effects include: Medications for the treatment of hypersensitivity reactions should be available.

Indication and Important Safety Information

The PBAC noted that while the overall rates of adverse events associated with canagliflozin and sitagliptin treatment were similar, there was a higher rate of genital mycotic infections in canagliflozin treatment groups.


Use of live vaccines could result in clinical infections, including disseminated infections. These hematomas may result in long-term or permanent paralysis. The PBAC invkkana canagliflozin is suitable for nurse practitioner prescribing for continuing therapy only. New onset or exacerbation of pre-existing diabetes mellitus ivokana hyperglycemia have been reported in patients receiving protease inhibitors. Control hypertension and correct hypokalemia before and during treatment.

Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Clinical Place for the Proposed Therapy Type 2 diabetes is a metabolic disorder characterised by hyperglycaemia resulting from resistance to the action of insulin, insufficient insulin secretion or both.

Overall, the PBAC did not consider that the claim that canagliflozin has a comparable safety profile to sitagliptin was adequately supported. In particular, the PBAC noted utilisation patterns indicating prescribing of some agents outside PBS restrictions, and considered this to be a matter of concern.

With regard to the comparative harms, the PBAC noted differences in the incidence of adverse events between the common comparator arms of the included trials, complicating the indirect comparison. Some cases had a fatal outcome. Effect of Daratumumab on Other Drugs: Before initiating, consider factors that may increase the risk of amputation, such as a history of prior amputation, peripheral vascular disease, neuropathy, and diabetic foot ulcers. Authority required To be finalised Consider supportive care with transfusions.

Skip to main content. Monitor patients closely for infections. Invokana comes as a tablet taken once daily by mouth. Falls were not associated with loss of consciousness or seizure.